Market Place
Sourcing Support
Idorsia’s Jean-Paul Clozel retires as CEO; CRISPR nabs CMO from Sanofi
24 May 2024 //
ENDPTS
Idorsia sleep survey will keep you up at night
01 Dec 2022 //
FIERCEPHARMA
A packed MS market is about to get busier as J&J`s ponesimod enters the fray
19 Mar 2021 //
ENDPTS
Beyond Batten Disease Foundation partners with Actelion on development
04 Mar 2021 //
PHARMAFILE
TRITON Phase 3b Study Results Presented at the European Society of Cardiology
28 Aug 2020 //
BUSINESSWIRE
Full Fed. Circ. Won`t Rehear Actelion Spinoff`s Patent Term Bid
30 Jul 2020 //
LAW360
Pivotal data suggest clean safety, potency could set Idorsia`s sleeping pill
21 Apr 2020 //
ENDPTS
J&J pitches its S1P1 MS drug into the regulatory ring as the competition heats
20 Mar 2020 //
ENDPTS
New OPSUMIT® (macitentan) Data Show Initial Combination Therapy with Tadalafil
21 Oct 2019 //
PR NEWSWIRE
J&J`s head-to-head PhIII data promise drug launch into crowded MS market
13 Sep 2019 //
ENDPOINTSNEWS
Copycats wanted: Pfizer, AZ and more under threat as China solicits generics
21 Jun 2019 //
FIERCE PHARMA
Owlstone Medical Enters into a Strategic Collaboration with Actelion
20 May 2019 //
BUSINESSWIRE
Owlstone Medical, Actelion team up for pulmonary hypertension detection
20 May 2019 //
PHARMA TIMES
Lupin-Natco get USFDA nod to market generic hypertension drug
30 Apr 2019 //
MONEYCONTROL
Orphazyme plans to pitch subgroup analyses of key study to regulators
31 Jan 2019 //
ENDPTS
NHS England to fund Actelion`s Uptravi
03 Jan 2019 //
Idorsia`s selatogrel hits goals in phase 2 cardiovascular trials
18 Dec 2018 //
FIERCE BIOTECH
J&J unit to pay $360 million to U.S. to resolve charity kickback probe
07 Dec 2018 //
REUTERS
Drug company Actelion to pay $360M in kickback probe
06 Dec 2018 //
ECONOMIC TIMES
J&J pays $500M in cash to grab rights to a new star cancer drug at argenx
03 Dec 2018 //
ENDPTS
Idorsia sheds surplus DMD therapy to Santhera
21 Nov 2018 //
FIERCE BIOTECH
Actelion`s Opsumit (macitentan) Receives Marketing Approval in EU
04 Oct 2018 //
EMA
Actelion’s Opsumit shows promise in portopulmonary hypertension
19 Sep 2018 //
PHARMA TIMES
First RCT in Pulm. Htn Shows macitentan Improves Pulmonary Vascular Resistance
17 Sep 2018 //
BUSINESSWIRE
J&J tops the pharma market cap charts Ð but for how long?
26 Jul 2018 //
PHARMAPHORUM
Azafaros to develop new treatments for rare metabolic disorders
23 Jul 2018 //
BIOSPECTRUM
J&J predicts 4% to 6% net price decline this year
18 Jul 2018 //
FIERCE PHARMA
PAH patients in England denied access to Actelion’s Uptravi on NHS
09 Jul 2018 //
PHARMA TIMES
FDA tries to shame drugmakers over tactics that delay generics
18 May 2018 //
FIERCE PHARMA
FDA ‘names and shames’ generic-blocking pharma companies
17 May 2018 //
PMLIVE
Actelion Submits sNDA to US FDA Seeking Approval of OPSUMIT® (macitentan)
30 Apr 2018 //
PR NEWSWIRE
J&J dumps a failed PhIII antibiotic program picked up in Actelion buyout
18 Apr 2018 //
ENDPTS
J&J scraps phase 3 antibiotic program acquired in $30B takeover
17 Apr 2018 //
FIERCE BIOTECH
Sanofi`s for-sale generics unit too pricey, ex-bidder says
23 Mar 2018 //
FIERCE PHARMA
Opsumit (Macitentan): Actelion Pharmaceuticals v. Zydus Pharmaceuticals (USA)
31 Jan 2018 //
PATENT LITIGATION
J&J takes $13.6 billion charge related to new U.S. tax law
24 Jan 2018 //
REUTERS
Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ
23 Jan 2018 //
PMLIVE
J&J adds PhIII hypertension drug to the pipeline with $230M-plus cash deal
04 Dec 2017 //
ENDPTS
Sanofi`s Bad End-of-the-Year Continues With Axing of Its C. Diff Drug
04 Dec 2017 //
BIOSPACE
Little Idorsia Scores $230M+ R&D Deal With Johnson & Johnson
04 Dec 2017 //
BIOSPACE
Trump tax reform uncertainty puts biotech M&A on hold
21 Aug 2017 //
PHARMAPHORUM
Kiadis Pharma proposes former Actelion COO Otto Schwarz new Board member
25 Jul 2017 //
BUSINESSINSIDER
Johnson & Johnson Closes Acquisition Of Actelion
16 Jun 2017 //
NASDAQ
EU clears J&J’s Actelion buy, with conditions
13 Jun 2017 //
PHARMA TIMES
Johnson & Johnson wins EU approval to buy Actelion
10 Jun 2017 //
GLOBAL
Actelion antibiotic misses mark on one study, hits it on another
09 Jun 2017 //
REUTERS
Tekni-Plex invests $15m in a Chinese manufacturing facility
08 Jun 2017 //
MANUFACTURING
Sanofi says has no `absolute need` to do acquisitions
11 May 2017 //
REUTERS
Janssen acquires over 90% of Actelion
24 Apr 2017 //
PHARMAFILE
J&J first quarter revenue misses estimates; new forecast includes Actelion
19 Apr 2017 //
REUTERS
About that pharma M&A comeback? Sorry. 2017`s not bringing it—at least not yet
11 Apr 2017 //
FIERCE PHARMA
EU safety review backs continued use Uptravi for PAH
10 Apr 2017 //
PHARMA TIMES
EMA Completes Postmarket Safety Review of Uptravi
08 Apr 2017 //
RAPS
Actelion’s Ledaga approved in EU for the treatment of MF-CTCL
07 Mar 2017 //
THE PHARMALETTER
Actelion Began in a Garage- Founding Couple Has $1 Billion & New Biotech Firm
03 Mar 2017 //
WALL STREET JOURNAL
Genmab and J&J`s cancer drug set for blockbuster sales this year
22 Feb 2017 //
REUTERS
How Sanofi blew its chance with Actelion
18 Feb 2017 //
DRUG DELIVERY
Sanofi backtracked on Actelion deal amid J&J talks
16 Feb 2017 //
BUSINESS LIVE
What`s wrong with Sanofi`s dealmaking approach? To hear Actelion tell it, plenty
16 Feb 2017 //
FIERCE PHARMA
